drugset / Trial / NCT06172322
A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single-arm phase 1b study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of NTQ1062 in combination with Fulvestrant in patients with locally advanced or metastatic HR positive/HER-2 negative breast cancer.
Timeline
- Start
- 2023-12-28
- Primary completion
- 2025-04
- Completion
- 2025-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NTQ1062 | Small molecule | — | Oral |
| Background | Fulvestrant | Small molecule | 500 mg | — |